Difference between revisions of "Team:Tuebingen/Basic Part"
| (4 intermediate revisions by 2 users not shown) | |||
| Line 11: | Line 11: | ||
padding: 0; | padding: 0; | ||
} | } | ||
| + | |||
| + | Css-> | ||
| + | |||
| + | #ImpressumSponsoren{ | ||
| + | bottom:0px; | ||
| + | margin-left: 25em; | ||
| + | margin-bottom: 5em; | ||
| + | margin-right: 10em; | ||
| + | text-align: right; | ||
| + | } | ||
#BigImageLab{ | #BigImageLab{ | ||
| Line 126: | Line 136: | ||
grid-template-rows: auto; | grid-template-rows: auto; | ||
margin-bottom: 5em; | margin-bottom: 5em; | ||
| − | margin-top: - | + | margin-top: -25em; |
} | } | ||
| Line 224: | Line 234: | ||
<a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | <a href="https://2017.igem.org/Team:Tuebingen/Inspiration"style="margin-right:1.5em;">Inspiration</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | <a href="https://2017.igem.org/Team:Tuebingen/Demonstrate"style="margin-right:1.5em;">Results</a> | ||
| − | <a href="https://2017.igem.org/Team:Tuebingen/HP | + | <a href="https://2017.igem.org/Team:Tuebingen/HP"style="margin-right:1.5em;">Human Practice</a> |
<a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | <a href="https://2017.igem.org/Team:Tuebingen/Lab"style="margin-right:1.5em;">Lab</a> | ||
<a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> | <a href="https://2017.igem.org/Team:Tuebingen/Attributions"style="margin-right:1.5em;">Attributions</a> | ||
| Line 317: | Line 327: | ||
| − | + | <div id="ImpressumSponsoren"> | |
| + | <img src="https://static.igem.org/mediawiki/2017/5/58/T%C3%BCbingen_Qiagen-Logo.jpeg" id="Quiagen" width=70px> <img src="https://static.igem.org/mediawiki/2017/1/1c/T%C3%BCbingen_Roth-Logo.jpeg" id="Roth" width=70px> <img src="https://static.igem.org/mediawiki/2017/d/d8/TuebingenZymoLogo.jpeg" width=150px> <img src="https://static.igem.org/mediawiki/2017/5/5b/T%C3%BCbingen_Eurofins-Logo.png" id="eurofins" width=150px> <img src="https://static.igem.org/mediawiki/2017/e/e4/GATCTuebingen.png" id="GATC" width=150px> <img src="https://static.igem.org/mediawiki/2017/4/49/T%C3%BCbingen_NEB-Logo.jpeg" id="BioLabs" width=150px><br><img src="https://static.igem.org/mediawiki/2017/7/7c/T%C3%BCbingen_Greiner-Logo.jpeg" id="Greiner" width=150px> <img src="https://static.igem.org/mediawiki/2017/b/bf/T%C3%BCbingen_Agilent-Logo.jpeg" id="Agilent" width=150px> <img src="https://static.igem.org/mediawiki/2017/0/01/T%C3%BCbingen_abcr-Logo.png" id="abcr" width=150px> <img src="https://static.igem.org/mediawiki/2017/5/59/MicrosynthTuebingen.png" width=150px> <img src="https://static.igem.org/mediawiki/2017/8/8b/Eppendorftuebingen.png" width=150px> | ||
| + | <div> <p> © iGEM Team Tuebingen 2017</p></div> | ||
</div> | </div> | ||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
Latest revision as of 12:38, 12 December 2017
basic parts
Basic Parts
SHV-1 is a β-lactamase that mediates resistance against ꞵ-lactams
CouL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics
CloL is a amide synthetase that catalyzes the bonding of the amide bonds in aminocoumarin antibiotics
β-lactam synthetase (BLS) catalyzes the formation of the β-lactam ring of clavulanic acid
The BLS mutant is a rationally designed mutant of the β-lactam synthetase
Gyrase B (GyrB)is a type II topoisomerase
Gyrase B (GyrB)is a type II topoisomerase
© iGEM Team Tuebingen 2017
